Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02909985 · ClinicalTrials.gov registry record · NA

Visual Activity Evoked by Infrared in Humans After Dark Adaptation

A NA study, sponsored by University of New Mexico.

Completed
Registry status
NA
Development phase
21
Enrollment target

NCT02909985: Completed NA study, sponsored by University of New Mexico.

NCT02909985 is a NA study that has completed, run by University of New Mexico. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02909985, a NA study, has completed, sponsored by University of New Mexico.

COMPLETED
Registry status
NA
Development phase
21 participants
Enrollment target

Study Summary

This pilot study will evaluate the visual response to infrared (IR) in humans after dark adaptation. The investigators plan to determine which wavelength and intensity the human eye is most sensitive to in healthy and color-blind participants by using a broad spectrum light source and wavelength-specific IR bandpass filters. The long-term goal of this research is to better understand the role that IR plays in visual function, and whether this can be manipulated to allow for vision in certain retinal pathologies that result from loss of photoreceptor cells. The investigators central objective is to test the electrophysiologic response to IR in the dark-adapted retinal and visual pathways. The investigator's central hypothesis is that IR evokes a visual response in humans after dark adaptation, and the characteristics of this response suggest transient receptor potential (TRP) channel involvement. The investigators rationale is that a better understanding of how IR impacts vision may allow for an alternative mechanism for vision in a number of diseases that cause blindness from the degradation or loss of function of photoreceptor cells. The investigators will test the investigator's hypothesis with the following Aims: Aim 1: Arm 1: To determine the optimal IR wavelength for visual perception in dark-adapted human participants. The investigators hypothesize that the healthy human eye will detect IR irradiation, with a maximum sensitivity at a specific wavelength. Using a broad-spectrum light source with wavelength-specific bandpass filters, the spectral range of visual perception to IR will be evaluated. Arm 2: To determine the optimal IR wavelength for visual perception in dark-adapted human participants who are colorblind. The investigators hypothesize that the colorblind human eye will detect IR irradiation, with a maximum sensitivity at a specific wavelength. Using a broad-spectrum light source with wavelength-specific bandpass filters, the spectral range of vi

Primary Outcome

We measured the minimum threshold intensities (uW) via subjective perception of near IR light (900 - 1400 nm) in 50 nm intervals. After 30 minutes of dark adaptation and over three trials, participants verbalized by saying 'yes' to the minimal intensity they could see the IR stimulus as the power source for the light was slowly increased from 0V to 12 V. The voltage was averaged for the three trials at each wavelength. Analysis of variance was used to evaluate the effect of the wavelength on the

Interventions

  • OTHER Tungsten halogen light with narrow bandpass filters

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2015-09
Est. Completion 2016-08
Phase NA
University of New Mexico

168 total trials

What the finished NCT02909985 record still lists

NCT02909985 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which Tungsten halogen light with narrow bandpass filters is the first listed.

NCT02909985 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02909985 about?

NCT02909985 is a clinical study titled "Visual Activity Evoked by Infrared in Humans After Dark Adaptation". This pilot study will evaluate the visual response to infrared (IR) in humans after dark adaptation. The investigators plan to determine which wavelength and intensity the human eye is most sensitive to in healthy and color-blind participants by using a broad spectrum light source and wavelength-spe...

What is the current status of trial NCT02909985?

This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2015-09. Estimated completion is 2016-08.

What interventions are being tested in trial NCT02909985?

The interventions under investigation include: Tungsten halogen light with narrow bandpass filters (OTHER).

Who is sponsoring clinical trial NCT02909985?

This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02909985's enrollment target sits among peer trials

21 1762nd of 2000 higher than 233 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02909985, the US trial registry maintained by the National Library of Medicine. NCT02909985 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.